Aims To measure the prevalence of beta‐blocker eye drop prescribing and respiratory effect
of ocular beta‐blocker administration in people with asthma. Methods We measured the …

Background Cardiovascular disease (CVD) is a common comorbidity in people with asthma.
However, safety concerns have caused heterogeneity in clinical guideline recommendations …

Introduction: Patients with asthma often have important co-morbidities which reduce the
likelihood of gaining optimal asthma control. Beta2-blockers are commonly prescribed for …

Purpose: To investigate the use of topical ocular anti-glaucoma medications by
glaucomatous patients with obstructive pulmonary disease and their effect on related …

Background and aim Recently, β-blockers have been suggested as a potential maintenance
treatment option for asthma. The aim of this review is to provide an overview of the current …

Background Asthma and chronic obstructive pulmonary disease (COPD), defined as
obstructive airways disease (OAD), are two common chronic conditions especially in the …

Background β-Blockers are avoided in asthma over concerns regarding acute
bronchoconstriction. Risk is greatest following acute exposure, including the potential for …

Background β-Antagonists have recently been proposed for the treatment of chronic asthma;
however, concerns regarding risk of acute bronchoconstriction in clinical trials remain …

Beta-adrenergic blocking agents (abbreviated as beta-blockers) have been used for treating
various cardiovascular diseases. However, the potential for asthma exacerbation is one of …

Background Inhaled short‐acting beta‐2 agonists are the major class of bronchodilators
used for relief of symptoms in asthma. There has been concern that excessive uncontrolled …